

NEW CMDHB SERVICE

ZOLEDRONATE (ACLASTA) INFUSION SUBSIDY SCHEME

CMDHB are offering a subsidised access for eligible patients to Zoledronate (Aclasta) infusions in the community.

To be eligible for the subsidy, the patient must meet following criteria:

- *Pharmac Special Authority application approved and*
- *Patient resident in CMDHB catchment area and*
- *Patients eGFR >35 and*
- *Patient holds a CSC card*

PLUS

- *Recommended by hospital specialist, including previous administration as an inpatient or outpatient*

or

- *Serious adverse reaction to Alendronate documented*

The infusion may be administered either by the patient's own GP or at an approved infusion centre and the subsidy claimable is \$80.00 incl GST.

Please refer to the attached documentation for further information, or view these online at www.primaryoptions.co.nz

Please note this service is facilitated by Primary Options, however is quite separate to the Primary Options for Acute Care service.

For further information, contact Deanna Williams (09) 535 7218 or email zoledronate@primaryoptions.co.nz